Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 3.10
AVEO's Cash to Debt is ranked higher than
64% of the 1275 Companies
in the Global Biotechnology industry.

( Industry Median: 69.96 vs. AVEO: 3.10 )
AVEO' s 10-Year Cash to Debt Range
Min: 1.54   Max: No Debt
Current: 3.1

Equity to Asset 0.40
AVEO's Equity to Asset is ranked higher than
59% of the 970 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. AVEO: 0.40 )
AVEO' s 10-Year Equity to Asset Range
Min: -3.21   Max: 0.79
Current: 0.4

-3.21
0.79
F-Score: 3
Z-Score: -8.37
M-Score: -4.06
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -291.99
AVEO's Operating margin (%) is ranked higher than
64% of the 1050 Companies
in the Global Biotechnology industry.

( Industry Median: -71.67 vs. AVEO: -291.99 )
AVEO' s 10-Year Operating margin (%) Range
Min: -8035.89   Max: 20.59
Current: -291.99

-8035.89
20.59
Net-margin (%) -303.15
AVEO's Net-margin (%) is ranked higher than
64% of the 1050 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. AVEO: -303.15 )
AVEO' s 10-Year Net-margin (%) Range
Min: -8277.57   Max: 18.59
Current: -303.15

-8277.57
18.59
ROE (%) -92.23
AVEO's ROE (%) is ranked higher than
60% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -33.71 vs. AVEO: -92.23 )
AVEO' s 10-Year ROE (%) Range
Min: -113.33   Max: 20.76
Current: -92.23

-113.33
20.76
ROA (%) -44.26
AVEO's ROA (%) is ranked higher than
67% of the 1279 Companies
in the Global Biotechnology industry.

( Industry Median: -27.24 vs. AVEO: -44.26 )
AVEO' s 10-Year ROA (%) Range
Min: -88.25   Max: 13.74
Current: -44.26

-88.25
13.74
ROC (Joel Greenblatt) (%) -350.00
AVEO's ROC (Joel Greenblatt) (%) is ranked higher than
74% of the 1249 Companies
in the Global Biotechnology industry.

( Industry Median: -347.70 vs. AVEO: -350.00 )
AVEO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1669.78   Max: 678.74
Current: -350

-1669.78
678.74
Revenue Growth (3Y)(%) -74.20
AVEO's Revenue Growth (3Y)(%) is ranked higher than
57% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: -0.50 vs. AVEO: -74.20 )
AVEO' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: -67.6
Current: -74.2

EBITDA Growth (3Y)(%) -2.30
AVEO's EBITDA Growth (3Y)(%) is ranked higher than
78% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. AVEO: -2.30 )
AVEO' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: -2.3
Current: -2.3

EPS Growth (3Y)(%) -3.00
AVEO's EPS Growth (3Y)(%) is ranked higher than
80% of the 708 Companies
in the Global Biotechnology industry.

( Industry Median: -8.20 vs. AVEO: -3.00 )
AVEO' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: -3
Current: -3

» AVEO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

AVEO Guru Trades in Q1 2014

Steven Cohen 500,000 sh (New)
Seth Klarman 3,829,350 sh (unchged)
Chuck Royce Sold Out
Jim Simons 1,275,453 sh (-1.82%)
Paul Tudor Jones 106,701 sh (-2.2%)
» More
Q2 2014

AVEO Guru Trades in Q2 2014

George Soros 49,076 sh (New)
Jim Simons 1,343,488 sh (+5.33%)
Seth Klarman 3,829,350 sh (unchged)
Paul Tudor Jones 106,701 sh (unchged)
» More
Q3 2014

AVEO Guru Trades in Q3 2014

Seth Klarman 3,829,350 sh (unchged)
George Soros Sold Out
Paul Tudor Jones 99,319 sh (-6.92%)
Jim Simons 591,700 sh (-55.96%)
» More
Q4 2014

AVEO Guru Trades in Q4 2014

Jim Simons 675,800 sh (+14.21%)
Seth Klarman Sold Out
Paul Tudor Jones 88,219 sh (-11.18%)
» More
» Details

Insider Trades

Latest Guru Trades with AVEO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Seth Klarman 2014-12-31 Sold Out 0.07%$0.65 - $1.17 $ 1.1729%0
George Soros 2014-09-30 Sold Out $1.09 - $1.79 $ 1.17-7%0
George Soros 2014-06-30 New Buy$1.02 - $1.72 $ 1.17-9%49076
Seth Klarman 2013-06-30 Reduce -21.9%0.26%$2.34 - $8.27 $ 1.17-73%3829350
George Soros 2011-12-31 Sold Out 0.0031%$14.53 - $17.35 $ 1.17-86%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.90
AVEO's P/B is ranked higher than
93% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 6.25 vs. AVEO: 1.90 )
AVEO' s 10-Year P/B Range
Min: 0.87   Max: 22.16
Current: 1.9

0.87
22.16
P/S 3.30
AVEO's P/S is ranked higher than
92% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 29.06 vs. AVEO: 3.30 )
AVEO' s 10-Year P/S Range
Min: 0.64   Max: 111.5
Current: 3.3

0.64
111.5
EV-to-EBIT -0.42
AVEO's EV-to-EBIT is ranked higher than
71% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. AVEO: -0.42 )
AVEO' s 10-Year EV-to-EBIT Range
Min: -8.1   Max: 16.9
Current: -0.42

-8.1
16.9
Current Ratio 1.84
AVEO's Current Ratio is ranked higher than
60% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.61 vs. AVEO: 1.84 )
AVEO' s 10-Year Current Ratio Range
Min: 1.55   Max: 9.47
Current: 1.84

1.55
9.47
Quick Ratio 1.84
AVEO's Quick Ratio is ranked higher than
62% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.41 vs. AVEO: 1.84 )
AVEO' s 10-Year Quick Ratio Range
Min: 1.55   Max: 9.47
Current: 1.84

1.55
9.47
Days Sales Outstanding 33.01
AVEO's Days Sales Outstanding is ranked higher than
91% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 114.29 vs. AVEO: 33.01 )
AVEO' s 10-Year Days Sales Outstanding Range
Min: 3.19   Max: 390.8
Current: 33.01

3.19
390.8

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.30
AVEO's Price/Net Cash is ranked higher than
89% of the 1357 Companies
in the Global Biotechnology industry.

( Industry Median: 56.66 vs. AVEO: 5.30 )
AVEO' s 10-Year Price/Net Cash Range
Min: 1.75   Max: 24.76
Current: 5.3

1.75
24.76
Price/Net Current Asset Value 4.90
AVEO's Price/Net Current Asset Value is ranked higher than
89% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 36.79 vs. AVEO: 4.90 )
AVEO' s 10-Year Price/Net Current Asset Value Range
Min: 1.62   Max: 24.22
Current: 4.9

1.62
24.22
Price/Tangible Book 1.80
AVEO's Price/Tangible Book is ranked higher than
94% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 9.29 vs. AVEO: 1.80 )
AVEO' s 10-Year Price/Tangible Book Range
Min: 1.2   Max: 14.66
Current: 1.8

1.2
14.66
Price/Median PS Value 0.80
AVEO's Price/Median PS Value is ranked higher than
92% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 2.46 vs. AVEO: 0.80 )
AVEO' s 10-Year Price/Median PS Value Range
Min: 0.18   Max: 25.39
Current: 0.8

0.18
25.39
Earnings Yield (Greenblatt) -227.90
AVEO's Earnings Yield (Greenblatt) is ranked lower than
53% of the 1255 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. AVEO: -227.90 )
AVEO' s 10-Year Earnings Yield (Greenblatt) Range
Min: -227.9   Max: 48134.7
Current: -227.9

-227.9
48134.7

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:VPA.Germany,
AVEO Pharmaceuticals Inc was incorporated under the laws of the State of Delaware on October 19, 2001 as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. on March 1, 2005. The Company is a cancer therapeutics company that discovers, develops and commercializes targeted cancer therapies to impact patients' lives. The Company's proprietary Human Response Platform provides the company unique insights into cancer and related disease biology and is being leveraged in the discovery and clinical development of its therapeutic candidates. Its product under development include: AV-203, an anti-ErbB3 monoclonal antibody with broad therapeutic potential. Ficlatuzumab, is a Hepatocyte Growth Factor, or HGF, inhibitory antibody. Tivozanib, is an investigational tyrosine kinase inhibitor of all three vascular endothelial growth factor, or VEGF receptors. AV-380, a potential first-in-class GDF-15 inhibitor, was discovered using proprietary Human Response Platform, that provides the company unique insights into cancer and related disease biology. The Company competes with Roche Laboratories, Inc., Pfizer Inc., Bayer HealthCare AG, Sanofi-Aventis, US, LLC, Amgen, Inc. and GlaxoSmithKline plc. The Company contracts with third parties for the manufacture of clinical product candidates. On March 9, 2014, Company entered into a manufacturing agreement with AbbVie Inc. for the process and development of AV-380. In August 2010, it entered into an agreement with Gallus BioPharmaceuticals, LLC for the clinical manufacture of AV-203 drug substance. The Company seeks trademark protection in the U.S. and foreign jurisdictions where available and when appropriate.
» More Articles for AVEO

Headlines

Articles On GuruFocus.com
Wild Card Wonders, Shopping for 52-Week Lows Sep 28 2013 
Sleepy Sector Wakes Up - Billionaires Hold Biotechs in 52-week Low Sep 03 2013 
comment on AVEO Mar 15 2013 
comment on AVEO Mar 15 2013 
Weekly CEO Buys Highlight: AVEO, ZAZA, TUES, TUES, FRAN, AKVA Dec 16 2012 
Seth Klarman’s Baupost Group Buys Microsoft Corp., BP, Allied Nevada Gold, Sells Audiovox Corp. Aug 12 2011 
Seth Klarman’s Baupost Group Q1 Portfolio Update; Buys ANV, SCMR, PDLI, AVEO May 14 2011 
AVEO Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 11 2011 
Two Picks from Seth Klarman: PDLI, AVEO Feb 22 2011 
Hedge Fund Baupost Group buys PDLI, AVEO, ALR, Sells LSTZA, UFS, SLRC, EXXI Feb 11 2011 

More From Other Websites
AVEO PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Feb 27 2015
AVEO Oncology to Host Conference Call to Discuss Presentation of Final Results and Biomarker... Feb 27 2015
AVEO Oncology to Host Conference Call to Discuss Presentation of Final Results and Biomarker... Feb 27 2015
Aveo Pharmaceuticals loses position in The Baupost Group Feb 11 2015
AVEO PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers Jan 23 2015
AVEO to Present at the 33rd Annual J.P. Morgan Healthcare Conference Jan 14 2015
AVEO PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Jan 13 2015
AVEO to Present at the 33rd Annual J.P. Morgan Healthcare Conference Jan 12 2015
AVEO Names Michael N. Needle, M.D., As Chief Medical Officer Jan 09 2015
AVEO Names Michael N. Needle, M.D., As Chief Medical Officer Jan 09 2015
AVEO Receives Confirmation of Eligibility for Submission of a Tivozanib Marketing Authorization... Jan 08 2015
BUZZ-U.S. STOCKS ON THE MOVE-Alkermes, Eli Lilly, Kalobios, Zafgen Jan 07 2015
AVEO PHARMACEUTICALS INC Files SEC form 8-K, Costs Associated with Exit or Disposal Activities,... Jan 07 2015
Aveo Oncology to cut two-thirds of workforce Jan 07 2015
AVEO Announces Executive Transition and Corporate Restructuring Jan 07 2015
AVEO Announces Executive Transition and Corporate Restructuring Jan 07 2015
Aveo Oncology gets initial warning from Nasdaq that it could be delisted Dec 30 2014
AVEO PHARMACEUTICALS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued... Dec 30 2014
AVEO PHARMACEUTICALS INC Financials Nov 18 2014
AVEO Gains on Tivozanib Agreement with Ophthotech Nov 13 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK